Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07033494 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 3 of 3 changed
See other at-risk trials from Merck (MSD)

Record History

  1. Primary endpoint(s) modified Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC · Completion pushed from Apr 30, 2029 to Apr 30, 2030 · Eligibility criteria expanded, about 17 words · 3 more Show 6 more changesShow less
    • Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC
    • Completion pushed from Apr 30, 2029 to Apr 30, 2030
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints revised (7)
    • Study description expanded, about 13 words
    • Site details revised at 3 of 80 sites
  2. Re-verified, no change to tracked fieldsv34
  3. Study sites: 79 to 80v33
  4. Study sites: 78 to 79v32
  5. Study sites revised (78)v31 See this version in full on ClinicalTrials.gov ↗
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 76 to 78v30
  2. Study sites: 75 to 76v29
  1. Trial sites expanded: 71 → 75 locationsv28
  2. Site details revised at 1 of 71 sitesv27
  3. Re-verified, no change to tracked fieldsv26
  4. Study sites: 70 to 71v25
  5. Study sites: 68 to 70v24
  6. Re-verified, no change to tracked fieldsv23
  7. Study sites: 66 to 68v22
  8. Study sites: 65 to 66v21
  9. Study sites: 64 to 65v20
  10. Study sites: 63 to 64v19
  11. Study sites revised (63)v18 See this version in full on ClinicalTrials.gov ↗
  12. Study sites: 59 to 63v17
  13. Study sites: 52 to 59v16
  14. Study sites: 44 to 52v15
  15. Study sites: 39 to 44v14
  16. Study sites: 35 to 39v13
  17. Study sites: 32 to 35v12
  18. Study sites: 29 to 32v11
  19. Study sites: 26 to 29v10
  20. Study sites: 23 to 26v9
  21. Study sites: 21 to 23v8
  22. Study sites: 16 to 21v7
  23. Study sites: 9 to 16v6
  24. Study sites: 3 to 9v5
  25. Re-verified, no change to tracked fieldsv4
  26. Study sites: 2 to 3v3
  27. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Primary and study completion dates: Sep 1, 2029 to Apr 30, 2029 · Start date changed from estimate of Jul 17, 2025 to Jul 16, 2025v2 Show 3 more changesShow less
    • Study sites: 0 to 2
    • Primary and study completion dates: Sep 1, 2029 to Apr 30, 2029
    • Start date changed from estimate of Jul 17, 2025 to Jul 16, 2025
  28. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Alzheimer's Disease
1,152 trials monitored
See 60 trials at risk
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD \& damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. * About the safety of MK-2214 and if people tolerate it
Trial Details
NCT Number NCT07033494
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Early Alzheimer's Disease
Enrollment 340 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov